New ART Agents: A Clinical Perspective

Volume 4, Issue 2.

Recently approved treatment options and new antiviral therapies still under investigation — through case-based discussion, Dr. Ethel Weld from the Division of Clinical Pharmacology and Infectious Diseases at the Johns Hopkins University School of Medicine explains how the promise of these new agents can impact current clinical practice.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

In The Clinic: Improving Outcomes in At-Risk Populations

Volume 3, Issue 8.

In this podcast Drs. Allison Agwu evaluates the specific barriers to testing and entering into care among transsexual individuals, migrant and immigrant populations, and adolescents.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

New Advances in ART

Volume 3, Issue 6.

In this podcast about ART, Dr. Rachel Simmons from Boston University School of Medicine discusses recent research that may improve clinicians’ ability to more effectively and more safely manage their patients with HIV infection.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

New Options for Patients with “Hard-To-Treat” Hepatitis C Infection

Volume 5, Issue 12.

In this podcast Dr. Ira Jacobson discusses New Options for Patients with “Hard-To-Treat” Hepatitis C Infection.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

HIV: Management of Concomitant Conditions

Volume 3, Issue 2.

In this podcast Dr. Alysse Wurcel discusses important drug-drug interactions that may impact the treatment of ischemic heart disease in people living with HIV, medication interactions that could influence the treatment of common comorbid diseases, and potential drug-drug interactions between antiretroviral agents and common over-the-counter medications.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study

Volume 4, Issue 8, Part 3.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting.

Resistance Analysis for Ledipasvir/Sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post Liver Transplant (SOLAR-1 and 2 STUDIES)

Volume 4, Issue 8, Part 2.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. Michael Charlton from Intermountain Medical Center about his abstract: Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected with Chronic HCV Who Have Advanced Liver Disease or are Post Liver Transplant(SOLAR-1 & 2 Studies), presented at the April 2016 EASL meeting.

High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals

Volume 4, Issue 8, Part 1.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting.

Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations

Volume 4, Issue 7.

Drs Paul Martin, MD and Kalyan Ram Bhamidimarri, MD cover the important topic of Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations in the format of case-study scenarios for the clinical practice.